Zhanel George G, Del Rosso James Q
Professor, Department of Medical Microbiology and Infectious Diseases, College of Medicine, Faculty of Health Sciences, University of Manitoba; Director of Canadian Antimicrobial Resistance Alliance, Manitoba, Canada;
Adjunct Clinical Professor (Dermatology), Touro University College of Osteopathic Medicine, Henderson, Nevada.
J Clin Aesthet Dermatol. 2016 Mar;9(3):42-7. Epub 2016 Mar 1.
Topical dapsone gel is a sulfone antibiotic approved for acne treatment. No microbiology studies were conducted during dapsone gel clinical trials and it is unclear whether 1) dapsone has antimicrobial activity that may be of clinical relevance in dermatology and 2) dapsone could affect the normal microbiome of facial skin where it is most commonly applied. This study assessed the in vitro activity of dapsone versus Gram-positive and Gram-negative bacterial pathogens obtained from patients with infections.
CANWARD is a national, annual, and ongoing surveillance system to assess the patterns of antibiotic-resistant pathogens in Canada. In 2014, 15 tertiary care medical centers collected 3,511 isolates from blood, respiratory tract, urine, and wounds. Antimicrobial susceptibility was assessed using CLSI broth microdilution method.
Dapsone demonstrated relatively poor activity versus Gram-negative bacilli with most MIC50, MIC90 in the range of 512μg/mL and >512μg/mL, respectively. In contrast, dapsone demonstrated activity versus Gram-positive cocci, such as Staphylococcus (including methicillin-resistant S. aureus [MRSA], methicillin-sensitive S. aureus [MSSA]), Streptococcus, and Enterococcus-several strains of S. epidermidis had MICs of 32 and 64μg/mL; there were strains of E. faecalis with MICs of 8, 16, 32, and 64μg/mL; and several strains of S. agalactiae and S. pyogenes demonstrated dapsone MICs of 4, 8, 16, 32, and 64μg/mL.
Dapsone has demonstrated antimicrobial activity in vitro. Whether this activity is part of the mechanism of action of topical dapsone in acne remains unknown. There are limited cutaneous pharmacokinetic data with topical dapsone including skin concentrations achieved with topical dapsone therapy; however, topical dapsone as a 2% nanoemulsion has shown very high (1196-3837.34μg/cm(2)) local skin concentrations. At these high concentrations, topical dapsone would be expected to affect the skin flora of patients with acne (especially Gram-positive cocci, such as Staphylococcus and Streptococcus). These concentrations are multiple times higher (20x-1000x) than the dapsone MICs found for many MSSA, MRSA, S. epidermidis, S. agalactiae, and S. pyogenes, any of which may be present on the skin of acne patients. Whether this results in resistance to dapsone or more importantly results in resistance to chemically unrelated antimicrobials is currently unknown.
外用氨苯砜凝胶是一种被批准用于治疗痤疮的砜类抗生素。在氨苯砜凝胶临床试验期间未进行微生物学研究,目前尚不清楚:1)氨苯砜是否具有可能在皮肤病学中具有临床相关性的抗菌活性;2)氨苯砜是否会影响其最常应用部位面部皮肤的正常微生物群。本研究评估了氨苯砜对从感染患者中分离出的革兰氏阳性和革兰氏阴性细菌病原体的体外活性。
CANWARD是一个全国性的、年度性的持续监测系统,用于评估加拿大抗生素耐药病原体的模式。2014年,15个三级医疗中心从血液、呼吸道、尿液和伤口中收集了3511株分离菌。使用CLSI肉汤微量稀释法评估抗菌药物敏感性。
氨苯砜对革兰氏阴性杆菌的活性相对较差,大多数MIC50、MIC90分别在512μg/mL和>512μg/mL范围内。相比之下,氨苯砜对革兰氏阳性球菌具有活性,如葡萄球菌(包括耐甲氧西林金黄色葡萄球菌[MRSA]、甲氧西林敏感金黄色葡萄球菌[MSSA])、链球菌和肠球菌——几种表皮葡萄球菌菌株的MIC为32和64μg/mL;粪肠球菌菌株的MIC为8、16、32和64μg/mL;几种无乳链球菌和化脓性链球菌菌株的氨苯砜MIC为4、8、16、32和64μg/mL。
氨苯砜在体外已显示出抗菌活性。这种活性是否是外用氨苯砜治疗痤疮作用机制的一部分尚不清楚。外用氨苯砜的皮肤药代动力学数据有限,包括外用氨苯砜治疗所达到的皮肤浓度;然而,2%纳米乳剂形式的外用氨苯砜已显示出非常高的(1196 - 3837.34μg/cm²)局部皮肤浓度。在这些高浓度下,外用氨苯砜预计会影响痤疮患者的皮肤菌群(尤其是革兰氏阳性球菌,如葡萄球菌和链球菌)。这些浓度比许多MSSA、MRSA、表皮葡萄球菌、无乳链球菌和化脓性链球菌的氨苯砜MIC高出数倍(20倍 - 1000倍),这些细菌中的任何一种都可能存在于痤疮患者的皮肤上。目前尚不清楚这是否会导致对氨苯砜产生耐药性,或者更重要的是是否会导致对化学上无关的抗菌药物产生耐药性。